Institutional development · Research, innovation and assessment · United Kingdom
Cambridge and UCL use stored blood samples to trace leukaemia years before diagnosis
A University of Cambridge and UCL team, publishing in Nature, used annually collected blood samples to reconstruct how acute myeloid leukaemia develops in the years before it is diagnosed.
Why it matters: Researchers studying blood cancer gain a year-by-year account of how AML-linked mutations arose and expanded before diagnosis, drawn from stored trial samples.
A team from the University of Cambridge and University College London (UCL) published research in Nature using blood samples collected each year, some taken 15 years before diagnosis, to trace the development of acute myeloid leukaemia (AML).
The researchers combined ultra-sensitive DNA sequencing with mathematical modelling to estimate when each mutation appeared and how fast affected cells grew and competed with other blood cells before diagnosis.
The samples came from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which involved around 50,000 women, according to the university.
The university said the discovery could help predict whether a person will develop the disease years or decades before symptoms, raising the possibility of prevention.
Editor’s view
Scott James, Research and Innovation Editor
For researchers working on AML, which the university says affects around 2,700 people in the UK each year, the study offers a step-by-step record of mutation growth before diagnosis. If its predictive potential is confirmed, the team says it could open the way to preventing the disease before it develops.